New patient studies surrounding Retatrutide , specifically the high-dose formulation ZPHC ZPHC, suggest a impressive benefit on physique loss and linked health illnesses . Scientists believe that this dual agonist , targeting both GLP-1 and GIP receptors , could provide a noteworthy improvement in the approach of excess weight and related disease